We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Findings Raise More Questions on Ketek Approval, Grassley Says
Findings Raise More Questions on Ketek Approval, Grassley Says
December 26, 2007
The FDA relied heavily on foreign postmarketing safety information for sanofi-aventis’ antibiotic Ketek and mismanaged investigating concerns of clinical trials of the drug, Sen. Chuck Grassley (R-Iowa) said.